Detection of circulating tumour cells in cerebrospinal fluid (CSFCTs) to diagnose leptomeningeal metastases (LM) among breast cancer patients a pilot study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON20288

Enrollment

Registered

2016-01-12

Start date

2016-01-19

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leptomeningeal metastases among breast cancer patients Nederlands: Leptomeningeale metastasen bij patienten met mammacarcinoom.

Interventions

Draw extra liquor for CSFCT during regular LP.

Eligibility

Inclusion criteria

Inclusion criteria: - Breast cancer patients with clinical suspicion of leptomeningeal metastases (LM) who are planned to undergo a lumbar puncture to confirm/exclude the diagnosis LM. - Signed informed consent.

Exclusion criteria

Exclusion criteria: - Contra-indication for lumbar puncture (on the discretion of the treating neurologist).

Design outcomes

Primary

Measure	Time frame
The detection rate of leptomeningeal metastases as the presence of at least 1 CSFCT in liquor (independent of volume) by the CellSearch method in patients with negative CSF cytology.	—

Secondary

Measure	Time frame
Molecular analysis of CSFCT and CTCs	—

Contacts

Public ContactA. Jager

Erasmus MC, Room 471

a.jager@erasmusmc.nlTel 010 704 17 33

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)